{
    "ticker": "GRX",
    "name": "GlycoMimetics, Inc.",
    "description": "GlycoMimetics, Inc. is a biotechnology company focused on the discovery and development of novel glycomimetic drugs for the treatment of cancer and other diseases. Founded in 2003, GlycoMimetics has pioneered the use of glycomimetics to target carbohydrate-protein interactions, a critical area of research for many therapeutic applications. The company\u2019s lead product candidate, uproleselan (GMI-1271), is an innovative therapy designed to enhance the efficacy of existing cancer treatments by targeting the underlying mechanisms that enable cancer cells to survive and proliferate. GlycoMimetics is committed to advancing its pipeline of drug candidates through clinical development and into the marketplace, aiming to improve the lives of patients suffering from serious conditions. The company\u2019s strategy involves leveraging its proprietary platform to create a diverse portfolio of drug candidates that can address significant unmet medical needs in oncology and beyond. With a strong emphasis on scientific innovation and collaboration, GlycoMimetics seeks to establish partnerships with other biopharmaceutical companies and research institutions to enhance its drug development efforts and bring its novel therapies to market.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rockville, Maryland, USA",
    "founded": "2003",
    "website": "https://www.glycomimetics.com",
    "ceo": "Rachel King",
    "social_media": {
        "twitter": "https://twitter.com/GlycoMimetics",
        "linkedin": "https://www.linkedin.com/company/glycomimetics/"
    },
    "investor_relations": "https://investors.glycomimetics.com",
    "key_executives": [
        {
            "name": "Rachel King",
            "position": "CEO"
        },
        {
            "name": "Helen Thackray",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "Uproleselan (GMI-1271)"
            ]
        }
    ],
    "seo": {
        "meta_title": "GlycoMimetics, Inc. | Innovative Glycomimetic Drugs for Cancer Treatment",
        "meta_description": "Explore GlycoMimetics, Inc., a biotechnology company specializing in glycomimetic drugs for cancer. Learn about their innovative therapies and commitment to patient care.",
        "keywords": [
            "GlycoMimetics",
            "Glycomimetic Drugs",
            "Oncology",
            "Biotechnology",
            "Cancer Treatment",
            "Uproleselan"
        ]
    },
    "faq": [
        {
            "question": "What is GlycoMimetics known for?",
            "answer": "GlycoMimetics is known for developing novel glycomimetic drugs for cancer treatment."
        },
        {
            "question": "Who is the CEO of GlycoMimetics?",
            "answer": "Rachel King is the CEO of GlycoMimetics, Inc."
        },
        {
            "question": "Where is GlycoMimetics headquartered?",
            "answer": "GlycoMimetics is headquartered in Rockville, Maryland, USA."
        },
        {
            "question": "What are GlycoMimetics' main products?",
            "answer": "GlycoMimetics' main product candidate is Uproleselan (GMI-1271)."
        },
        {
            "question": "When was GlycoMimetics founded?",
            "answer": "GlycoMimetics was founded in 2003."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "GILD",
        "MRNA"
    ],
    "related_stocks": [
        "REGN",
        "NVS",
        "ABBV",
        "PFE"
    ]
}